Toggle Main Menu Toggle Search

Open Access padlockePrints

Results of the Phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

Lookup NU author(s): Dr Jingky Lozano-KuehneORCiD, Dr Nicola Cresti, Professor Ruth Plummer

Downloads

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Publication metadata

Author(s): Coombes RC, Badman P, Lozano-Kuehne JP, Macpherson IRJ, Zubairi I, Baird RD, Garcia-Corbacho J, Cresti N, Plummer R, Armstrong AC, Allerton R, Landers D, McLellan L, Lim A, Mouliere F, Seckl M

Publication type: Article

Publication status: Published

Journal: Nature Communications

Year: 2022

Volume: 13

Online publication date: 10/06/2022

Acceptance date: 12/05/2022

Date deposited: 01/10/2022

ISSN (electronic): 2041-1723

Publisher: Nature Publishing Group

URL: https://doi.org/10.1038/s41467-022-30666-0

DOI: 10.1038/s41467-022-30666-0

Altmetrics

Altmetrics provided by Altmetric

Funding

Funder referenceFunder name
Astrazeneca (AZ)
A.A. has received grant funding to her Institution from AZ.
D.L. consults to Astrazeneca (AZ) and was an employee in the past. His research team has also received grant funding from AZ.
R.B. consults to AZ and has received grant funding, travel, accommodation, expenses from AZ.

Share